Allergan, Inc.

Ipsen Bioinnovation Limited

The Secretary of State for Health

Roger Kei Aoki

Minglei Cui

Stephen W Jenkins

Patrick Michael Hughes

James Nienyuan Chang

Michael R Robinson

Scott M Whitcup

Wendy M Blanda

Terrence J Hunt

Lance Steward

Joseph Francis

Keith Foster

John Andrew Chaddock

Philip Marks

Judith M Leon

Steven R Carlson

Michael W Grayston

Patrick Stancombe

Peter James

Charles Penn

Single chain polypeptide fusion protein, comprising: a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety; a protease cleavage site; a translocation domain; a first spacer located between the non-cytotoxic protease and the protease cleavage site; and a second spacer located between the galanin targeting moiety and the translocation domain.

Fusion proteins comprising a non-cytotoxic protease, a translocation domain, and a targeting moiety that binds a galanin receptor and methods for treating, preventing or ameliorating pain using such fusion proteins

neurotoxin formulated with a hyaluronic acid carrier with increased residency time of thetoxin at a subdermal location and fewertoxin induced complications or side effects.

[object Object]

Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.

Botulinum toxin formulation

Methods for treating a non-spasm caused pain by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin.

Neuropathic pain treatment method

Method for treating allodynia by peripheral administration of a neurotoxin

Method for treating hyperalgesia by peripheral administration of a neurotoxin

Growing community of inventors

Coto de Caza, CA, United States of America

Roger Kei Aoki